Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Multi-kinase inhibitor

Cabometyx (cabozantinib)

An approved treatment for Neuroendocrine Tumors.

FDA Approved (2016)by Exelixis
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2016

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Cabozantinib wherever you encounter it, plus the key facts at a glance.

Generic name
Cabozantinib
Brand name
Cabometyx
Development code
XL184
Drug class
Multi-kinase inhibitor
Manufacturer
Exelixis
How it's taken
Oral tablet, once a day on an empty stomach

A once-daily tablet approved for adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors that started in the pancreas (pNET) or outside it (epNET)[1].

  • Unresectable means surgery cannot safely remove the tumor.
  • The FDA added these uses on March 26, 2025, based on the CABINET trial[3][2].
  • The same tablets are approved for advanced kidney cancer, for liver cancer after sorafenib and for differentiated thyroid cancer, uses that have no page on Trial Friend[1].
  • The current Cabometyx label has no boxed warning, and its warnings include serious bleeding, tears and abnormal openings in the gut, blood clots, high blood pressure and heart failure[1].
  • Cabometyx tablets and Cometriq capsules contain the same medicine, but the Cabometyx label says not to substitute one for the other[1].
Follow Cabometyx by email

We'll email you when Cabometyx's FDA label changes, when the FDA acts on it, and when new trials for Neuroendocrine Tumors open. Unsubscribe anytime.

You'll get, for Neuroendocrine Tumors:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Cabozantinib fits

Cabometyx (cabozantinib) is a daily kinase inhibitor tablet approved since March 26, 2025 for adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors[1][3].

  • Somatuline Depot (lanreotide) is a somatostatin analog injection approved for adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic NETs[9].
  • Lutathera (lutetium Lu 177 dotatate) is a radioactive infusion approved for adults and children 12 and older with somatostatin receptor-positive gastroenteropancreatic NETs[10].
  • Afinitor (everolimus) is approved for adults with progressive pancreatic NETs and progressive, well-differentiated, non-functional NETs of gut or lung origin that cannot be removed or have spread[11].
  • Sutent (sunitinib) is approved for adults with progressive, well-differentiated pancreatic NETs that cannot be removed or have spread[12].
  • Welireg (belzutifan) covers pancreatic NETs only in adults with von Hippel-Lindau disease who do not need surgery right away[13].
  • The CABINET trial compared Cabometyx with placebo in people who had already taken at least 1 approved treatment such as everolimus, sunitinib or Lutathera, and the Cabometyx label reports no trial comparing it directly with any of these drugs[1].
  • Anyone weighing Cabometyx can ask their oncologist where their tumor started, which earlier treatments count, and how the blood pressure checks and dose changes that most CABINET patients needed would fit their routine.

How Cabozantinib works

In laboratory tests, cabozantinib blocks the tyrosine kinase activity of MET, the VEGF receptors 1, 2 and 3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3 and TIE-2[1]. Tyrosine kinases are enzymes that pass growth signals inside cells. The Cabometyx label says these kinases take part in cancer growth and spread, in the growth of new blood vessels that feed tumors, in drug resistance and in keeping up the tissue around a tumor[1].

In neuroendocrine tumors the label does not require a gene test or a somatostatin receptor scan before treatment, and CABINET enrolled people with tumors that make hormones and tumors that do not[1].

Side effects and safety

What patients report
Label warnings
  • Serious bleeding. severe and fatal bleeding can occur; grade 3 to 5 bleeding in 5% across the kidney, liver and thyroid cancer studies; not given after recent bleeding, such as coughing up or vomiting blood or black stools, and stopped for grade 3 or 4 bleeding
  • Perforations and fistulas. tears in the gut in 1% and fistulas, abnormal openings between organs, in 1%, some fatal; Cabometyx is stopped for a gut tear or a grade 4 fistula
  • Blood clots. clots in veins in 7% (including 4% in the lungs) and in arteries in 2%, some fatal; stopped for a heart attack or a serious clot that needs treatment
  • High blood pressure. in 65% in CABINET, grade 3 in 26%; not started when blood pressure is uncontrolled, and stopped for a hypertensive crisis or blood pressure that cannot be controlled
  • Heart failure. a warning the label lists as changed in October 2025; can be severe and fatal; occurred in 0.5% of people taking Cabometyx alone, with a median onset at 73 days
  • Diarrhea. in 62% across studies, grade 3 in 10%; in CABINET 63% in the pancreatic group and 65% in the extra-pancreatic group
  • Hand-foot syndrome (palmar-plantar erythrodysesthesia). in 45% across studies, grade 3 in 13%; paused and restarted at a lower dose when it becomes intolerable
  • Protein in the urine. in 8%; Cabometyx is stopped for nephrotic syndrome
  • Osteonecrosis of the jaw. in less than 1%; an oral exam before and during treatment, and Cabometyx is held at least 3 weeks before dental surgery or invasive dental work
  • Slow wound healing. held at least 3 weeks before planned surgery and not given for at least 2 weeks after major surgery and until the wound heals
  • Reversible posterior leukoencephalopathy syndrome (RPLS). brain swelling seen on MRI, with seizures, headache, vision changes or confusion; Cabometyx is stopped
  • Thyroid problems. mostly an underactive thyroid, in 19% across studies; thyroid function is checked before and during treatment
  • Low blood calcium. in 13% across studies; calcium is checked and replaced as needed
  • Growth plates in children. widening of the growth plates has been seen in children whose bones are still growing, so the label recommends growth monitoring
  • Pregnancy and breastfeeding. can harm an unborn baby; pregnancy status is checked before starting, effective contraception during treatment and for 4 months after the last dose, and no breastfeeding for the same time
Most common in trials
FatigueHigh blood pressureDiarrheaRash, including hand-foot syndromeMouth soresNauseaMuscle and joint painChanges in tasteDecreased appetiteUnderactive thyroidAbdominal painWeight lossDizzinessVomiting
What gets monitored
  • Blood pressure, regularly throughout treatment
  • Urine protein, regularly
  • Thyroid function, before starting and during treatment
  • Blood calcium, with replacement as needed
  • An oral exam before starting and from time to time during treatment
  • Heart pumping function (left ventricular ejection fraction), which the label says to consider at the start and from time to time
  • Growth and growth plates, in children whose bones are still growing
  • A pregnancy test before starting, for anyone who could become pregnant
Report a suspected reaction to Exelixis at 1-855-500-3935, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
Side effects in the trial, Cabometyx against placebo
CabometyxPlaceboShare of people in each group who reported it
Fatigue
79%
61%
High blood pressure
67%
55%
Diarrhea
63%
23%
Rash including hand-foot syndrome
57%
23%
Mouth sores
49%
10%
Muscle and joint pain
41%
19%
Nausea
37%
32%
Changes in taste
30%
6%
Bars run from 0% to 80%. A side effect can be more common in the placebo group, which can happen when the symptom comes from the disease itself or by chance.
In context

The current Cabometyx label has no boxed warning and lists no contraindications[1]. Its warnings cover severe and fatal bleeding; tears in the gut and fistulas, abnormal openings between organs (1% each); blood clots in veins (7%) and arteries (2%); high blood pressure, including hypertensive crisis; heart failure, a warning the label lists as changed in October 2025; severe diarrhea; hand-foot syndrome; protein in the urine; osteonecrosis of the jaw; slow wound healing; a brain swelling syndrome called RPLS; thyroid problems; low blood calcium; and harm to an unborn baby[1].

In CABINET, high blood pressure occurred in 65% of people on Cabometyx, grade 3 in 26%[1]. In the pancreatic NET group of 63 people on Cabometyx and 31 on placebo, the most common side effects were fatigue (79% against 61%), high blood pressure (67% against 55%), diarrhea (63% against 23%), rash including hand-foot syndrome (57% against 23%), mouth sores (49% against 10%), muscle and joint pain (41% against 19%), nausea (37% against 32%) and changes in taste (30% against 6%); blood clots occurred in 19% against 3.2%[1].

In the extra-pancreatic group of 132 people on Cabometyx and 67 on placebo, they were fatigue (73% against 58%), diarrhea (65% against 42%), high blood pressure (64% against 37%), rash including hand-foot syndrome (50% against 10%), mouth sores (40% against 10%), nausea (39% against 21%), muscle and joint pain (36% against 33%), changes in taste (35% against 1.5%), an underactive thyroid (34% against 4.5%) and decreased appetite (33% against 15%)[1].

Lab changes in CABINET included raised liver enzymes AST (76% in the pancreatic group and 70% in the extra-pancreatic group) and ALT (75% and 63%) and low platelets (37% and 55%)[1]. Serious side effects occurred in 46% of the pancreatic group and 44% of the extra-pancreatic group, and side effects led 19% and 28% to stop Cabometyx[1].

Doses were paused for side effects in 83% and 81% and lowered in 49% and 38%, and the median average daily dose was about 41mg to 43mg against the 60mg starting dose[1]. Side effects that led to death occurred in 4.5% of the extra-pancreatic group, 1 person each from liver failure, failure of several organs, bleeding in the gut, cardiac arrest, a burst aortic aneurysm and sudden death of unstated cause[1]. Since approval, aneurysms, dissections and ruptures of arteries, including the aorta, have been reported[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Cabozantinib

For neuroendocrine tumors, adults and children 12 and older who weigh 40kg or more take 60mg by mouth once a day, and children 12 and older who weigh less than 40kg take 40mg once a day, until the cancer grows or side effects become too much[1]. Cabometyx is taken on an empty stomach, at least 1 hour before or at least 2 hours after eating[1].

Tablets are swallowed whole and not crushed, chewed or split, and a missed dose is not taken within 12 hours of the next one[1]. The label says not to substitute Cabometyx tablets with cabozantinib capsules[1]. For serious or intolerable side effects, Cabometyx is paused and restarted at a lower dose: 60mg goes to 40mg, then 20mg, and a child's 40mg dose goes to 20mg, then 20mg every other day[1].

Cabometyx is stopped at least 3 weeks before planned surgery, including dental surgery, and not restarted for at least 2 weeks after major surgery and until the wound heals[1]. People with moderate liver impairment (Child-Pugh B) start 20mg lower, the label says to avoid Cabometyx with severe liver impairment, and no dose change is needed for mild or moderate kidney impairment[1].

The label says to avoid strong CYP3A4 inhibitors or lower the daily dose by 20mg, and to avoid strong or moderate CYP3A4 inducers or raise the daily dose by 20mg, to no more than 80mg a day[1]. Grapefruit, grapefruit juice and St. John's wort are also avoided[1]. Cabometyx comes as yellow 20mg, 40mg and 60mg tablets in bottles of 30[1].

Availability and cost

No generic available

Only available as the brand-name product.

Why it costs what it costs

A daily oral cancer drug. The label gives no price. Drugs@FDA lists final approvals of generic cabozantinib tablets from MSN (August 14, 2026) and Cipla (October 16, 2026), both rated therapeutically equivalent to Cabometyx, but neither company has been confirmed to be selling them[7][8]. Exelixis Access Services offers a co-pay program for commercially insured patients, free drug for some people who qualify, and, according to its page for doctors, a free trial supply for new patients and up to 3 more 15-day supplies when an insurer takes 5 days or more to decide[14][15].

Help paying for Cabometyx

With private insurance, the drugmaker's copay card can lower what you pay for Cabometyx. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Neuroendocrine Tumors was not taking new applications on November 17, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Cabometyx (Cabozantinib)
Some details not published
Exelixis Access Services (EASE)
  • Copay help

    EASE Co-Pay Program: eligible commercially insured patients may pay as little as $0 per month. Annual and transaction limits apply but are not stated on the page. Not available to patients with federal, state or other government-funded insurance, or where prohibited by law.

    For: private insurance · source
  • Free medicine program

    EASE Patient Assistance Program: may provide Cabometyx free of charge to patients who qualify. No income limit is published. The doctor's office starts the EASE Enrollment Form.

    For: no insurance, underinsured · source
  • Other support

    EASE's page for doctors describes a free trial for new Cabometyx patients regardless of insurance type, limited to on-label uses, with up to 3 more 15-day supplies when the insurer takes 5 days or more to decide, and a free 15-tablet lower-dose supply for a dose reduction (unused tablets are returned).

    For: private insurance, Medicare, Medicaid, TRICARE, no insurance · source
  • Insurance and case manager help

    An EASE case manager can explain whether insurance covers Cabometyx and what it may cost. Phone 1-844-900-EASE (1-844-900-3273), 8:00 AM to 8:00 PM ET, Monday to Friday. The Patient Authorization Form is faxed to 1-844-901-EASE.

    The official page does not say who qualifies. Ask the program. · source

Good to know: Read on cabometyx.com/cost-financial-support and ease.us/cabometyx on November 17, 2026. No co-pay maximum or income limit is published. The trial supply and dose exchange appear only on the page for doctors. Patients on Cabometyx with Opdivo get Opdivo support at 1-800-861-0048.

Checked on the drugmaker's official pages on November 17, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Neuroendocrine Tumors

  • From a charity · The Assistance Fund
    Neuroendocrine Tumors fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 17, 2026.

Every program and charity fund for Neuroendocrine Tumors →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Access and eligibility

Manufacturer
Exelixis
Eligibility requirement

Approved for adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors[1]. The label does not list which earlier treatments count; in CABINET everyone had taken at least 1 FDA-approved treatment other than a somatostatin analog[1]. Children 12 and older are dosed by weight, and safety and effectiveness under 12 have not been established[1]. The label says to avoid Cabometyx with severe liver impairment and has no experience with severe kidney impairment[1]. CABINET did not enroll people with active brain metastases, earlier cabozantinib, significant gut bleeding or tumors growing into the gut or around major blood vessels[1].

Source: Exelixis Access Services

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

The CABINET trial (NCT03375320), sponsored by the National Cancer Institute, was a double-blind trial that randomized people 2 to 1 to Cabometyx 60mg or placebo once a day[5][1]. It enrolled 2 groups of people whose well-differentiated neuroendocrine tumors could not be removed or had spread and had grown after at least 1 earlier FDA-approved treatment other than a somatostatin analog[1][4].

In the pancreatic group of 99 people, all had taken everolimus, sunitinib or Lutathera before, and Cabometyx lengthened progression-free survival, the time before the cancer grew, to a median of 13.8 months against 3.3 months on placebo (hazard ratio 0.22)[1]. Tumors shrank in 18% on Cabometyx against 0% on placebo, and those responses lasted a median of 11.4 months[1].

In the extra-pancreatic group of 199 people, who had taken everolimus or Lutathera before, the median was 8.5 months against 4.2 months (hazard ratio 0.40), and tumors shrank in 5% against 0%[1]. Their tumors started most often in the small bowel (34%) or lung (20%)[1]. Overall survival was not yet mature in either group (hazard ratios 1.01 and 1.05), and 52% and 37% of people on placebo switched to Cabometyx after their cancer grew, which the label says may affect the survival comparison[1][3].

A stable dose of a somatostatin analog for symptom control was allowed[1]. The trial left out people with active brain metastases, earlier cabozantinib, significant bleeding in the gut, or tumors growing into the gut or around major blood vessels[1]. The approval for children 12 and older rests on the adult results plus drug level data, since CABINET enrolled adults[1].

Development history

Cometriq capsules are printed with the code XL184, the name cabozantinib carried in development[6]. The FDA first approved cabozantinib as Cometriq capsules in 2012 for medullary thyroid cancer, then approved Cabometyx tablets under a separate application on April 25, 2016, after a priority review[2]. Drugs@FDA lists new Cabometyx uses added in December 2017, January 2019, January 2021 and September 2021[2].

The CABINET trial, run through the National Cancer Institute, began in October 2018, and its results appeared in The New England Journal of Medicine in February 2025[5][4]. The FDA approved the neuroendocrine tumor uses on March 26, 2025, reviewed alongside Australia's TGA and Switzerland's Swissmedic under Project Orbis[3][2]. The Cabometyx label updated in October 2025 lists a change to its heart failure warning[1]. Drugs@FDA lists final approvals of generic cabozantinib tablets from MSN on August 14, 2026 and Cipla on October 16, 2026[7][8].

Ask anything about Cabozantinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Neuroendocrine Tumors trials

Other Neuroendocrine Tumors treatments

Common questions about Cabozantinib

▸What is Cabozantinib (Cabometyx)?

A once-daily tablet approved for adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors that started in the pancreas (pNET) or outside it (epNET)[1]. Unresectable means surgery cannot safely remove the tumor. The FDA added these uses on March 26, 2025, based on the CABINET trial[3][2]. The same tablets are approved for advanced kidney cancer, for liver cancer after sorafenib and for differentiated thyroid cancer, uses that have no page on Trial Friend[1]. The current Cabometyx label has no boxed warning, and its warnings include serious bleeding, tears and abnormal openings in the gut, blood clots, high blood pressure and heart failure[1]. Cabometyx tablets and Cometriq capsules contain the same medicine, but the Cabometyx label says not to substitute one for the other[1].

▸How does Cabozantinib work?

In laboratory tests, cabozantinib blocks the tyrosine kinase activity of MET, the VEGF receptors 1, 2 and 3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3 and TIE-2[1]. Tyrosine kinases are enzymes that pass growth signals inside cells. The Cabometyx label says these kinases take part in cancer growth and spread, in the growth of new blood vessels that feed tumors, in drug resistance and in keeping up the tissue around a tumor[1]. In neuroendocrine tumors the label does not require a gene test or a somatostatin receptor scan before treatment, and CABINET enrolled people with tumors that make hormones and tumors that do not[1].

▸What are the side effects of Cabozantinib?

The current Cabometyx label has no boxed warning and lists no contraindications[1]. Its warnings cover severe and fatal bleeding; tears in the gut and fistulas, abnormal openings between organs (1% each); blood clots in veins (7%) and arteries (2%); high blood pressure, including hypertensive crisis; heart failure, a warning the label lists as changed in October 2025; severe diarrhea; hand-foot syndrome; protein in the urine; osteonecrosis of the jaw; slow wound healing; a brain swelling syndrome called RPLS; thyroid problems; low blood calcium; and harm to an unborn baby[1]. In CABINET, high blood pressure occurred in 65% of people on Cabometyx, grade 3 in 26%[1]. In the pancreatic NET group of 63 people on Cabometyx and 31 on placebo, the most common side effects were fatigue (79% against 61%), high blood pressure (67% against 55%), diarrhea (63% against 23%), rash including hand-foot syndrome (57% against 23%), mouth sores (49% against 10%), muscle and joint pain (41% against 19%), nausea (37% against 32%) and changes in taste (30% against 6%); blood clots occurred in 19% against 3.2%[1]. In the extra-pancreatic group of 132 people on Cabometyx and 67 on placebo, they were fatigue (73% against 58%), diarrhea (65% against 42%), high blood pressure (64% against 37%), rash including hand-foot syndrome (50% against 10%), mouth sores (40% against 10%), nausea (39% against 21%), muscle and joint pain (36% against 33%), changes in taste (35% against 1.5%), an underactive thyroid (34% against 4.5%) and decreased appetite (33% against 15%)[1]. Lab changes in CABINET included raised liver enzymes AST (76% in the pancreatic group and 70% in the extra-pancreatic group) and ALT (75% and 63%) and low platelets (37% and 55%)[1]. Serious side effects occurred in 46% of the pancreatic group and 44% of the extra-pancreatic group, and side effects led 19% and 28% to stop Cabometyx[1]. Doses were paused for side effects in 83% and 81% and lowered in 49% and 38%, and the median average daily dose was about 41mg to 43mg against the 60mg starting dose[1]. Side effects that led to death occurred in 4.5% of the extra-pancreatic group, 1 person each from liver failure, failure of several organs, bleeding in the gut, cardiac arrest, a burst aortic aneurysm and sudden death of unstated cause[1]. Since approval, aneurysms, dissections and ruptures of arteries, including the aorta, have been reported[1].

▸How is Cabozantinib taken?

For neuroendocrine tumors, adults and children 12 and older who weigh 40kg or more take 60mg by mouth once a day, and children 12 and older who weigh less than 40kg take 40mg once a day, until the cancer grows or side effects become too much[1]. Cabometyx is taken on an empty stomach, at least 1 hour before or at least 2 hours after eating[1]. Tablets are swallowed whole and not crushed, chewed or split, and a missed dose is not taken within 12 hours of the next one[1]. The label says not to substitute Cabometyx tablets with cabozantinib capsules[1]. For serious or intolerable side effects, Cabometyx is paused and restarted at a lower dose: 60mg goes to 40mg, then 20mg, and a child's 40mg dose goes to 20mg, then 20mg every other day[1]. Cabometyx is stopped at least 3 weeks before planned surgery, including dental surgery, and not restarted for at least 2 weeks after major surgery and until the wound heals[1]. People with moderate liver impairment (Child-Pugh B) start 20mg lower, the label says to avoid Cabometyx with severe liver impairment, and no dose change is needed for mild or moderate kidney impairment[1]. The label says to avoid strong CYP3A4 inhibitors or lower the daily dose by 20mg, and to avoid strong or moderate CYP3A4 inducers or raise the daily dose by 20mg, to no more than 80mg a day[1]. Grapefruit, grapefruit juice and St. John's wort are also avoided[1]. Cabometyx comes as yellow 20mg, 40mg and 60mg tablets in bottles of 30[1].

▸Is Cabozantinib FDA approved?

Yes. The FDA approved Cabometyx for neuroendocrine tumors on March 26, 2025, for adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic (epNET) neuroendocrine tumors.

Previously treated: in the CABINET trial everyone had taken at least 1 FDA-approved treatment other than a somatostatin analog.

Other uses: the same tablets were first approved in 2016 and also cover advanced kidney cancer, liver cancer after sorafenib and differentiated thyroid cancer.

Tablets only: the label says not to substitute Cabometyx tablets with cabozantinib capsules such as Cometriq.

Children: dosed by weight from age 12; not established under 12.

Source: Cabometyx prescribing information and FDA announcement, March 26, 2025

▸How well did Cabometyx work for neuroendocrine tumors?

In the CABINET trial, Cabometyx delayed tumor growth against placebo in both pancreatic and extra-pancreatic NETs[1].

Pancreatic NETs: median progression-free survival 13.8 months against 3.3 months (hazard ratio 0.22), and tumors shrank in 18% against 0%.

Extra-pancreatic NETs: median 8.5 months against 4.2 months (hazard ratio 0.40), and tumors shrank in 5% against 0%.

Overall survival: not yet mature in either group, and many people on placebo later switched to Cabometyx.

Who joined: people whose tumors had grown after at least 1 earlier approved treatment other than a somatostatin analog.

Source: Cabometyx prescribing information

▸What is the Cabometyx dose for neuroendocrine tumors?

The label dose is 60mg by mouth once a day for adults and for children 12 and older who weigh 40kg or more, and 40mg once a day for children 12 and older under 40kg[1].

Food: taken at least 1 hour before or at least 2 hours after eating.

Tablets: swallowed whole, never crushed, chewed or split.

Missed dose: not taken within 12 hours of the next dose.

Dose changes: lowered to 40mg, then 20mg, for side effects; in CABINET the median average daily dose was about 41mg to 43mg.

Surgery: stopped at least 3 weeks before planned surgery, including dental surgery.

Source: Cabometyx prescribing information

▸What are the side effects of Cabometyx in neuroendocrine tumors?

Fatigue, high blood pressure, diarrhea, rash including hand-foot syndrome and mouth sores were the most common side effects in CABINET[1].

Blood pressure: high in 65% of people on Cabometyx, grade 3 in 26%.

Serious side effects: in 46% of the pancreatic group and 44% of the extra-pancreatic group.

Stopping: side effects led 19% and 28% to stop Cabometyx.

Warnings: serious bleeding, gut tears and fistulas, blood clots, heart failure, jaw bone damage, slow wound healing and harm to an unborn baby.

Boxed warning: none on the current label.

Source: Cabometyx prescribing information

▸Is Cabometyx the same as Cometriq?

Both contain cabozantinib, but they are different products with different approved uses, and the Cabometyx label says not to substitute Cabometyx tablets with cabozantinib capsules[1][6].

Cabometyx: tablets, 60mg once a day for NETs, approved for neuroendocrine tumors, kidney cancer, liver cancer and differentiated thyroid cancer.

Cometriq: capsules, 140mg once a day, approved for progressive, metastatic medullary thyroid cancer.

Food: Cabometyx is taken at least 1 hour before or 2 hours after eating; Cometriq needs no food for 2 hours before and 1 hour after.

Source: Cabometyx prescribing information and Cometriq prescribing information

▸Is there a generic for Cabometyx?

Drugs@FDA lists approved generic cabozantinib tablets, but none has been confirmed on sale[7][8].

MSN: approved August 14, 2026 and rated therapeutically equivalent to Cabometyx.

Cipla: approved October 16, 2026 and rated therapeutically equivalent to Cabometyx.

Capsules: generic tablets made to match Cabometyx are not substitutes for Cometriq capsules.

Source: Drugs@FDA ANDA 213878 and Drugs@FDA ANDA 217870

▸Is there help paying for Cabometyx?

Exelixis Access Services (EASE) offers a co-pay program, a patient assistance program and insurance help for Cabometyx[14].

Co-pay: eligible commercially insured patients may pay as little as $0 a month, with annual and transaction limits.

Not eligible for co-pay help: people with federal, state or other government-funded insurance.

Free drug: the patient assistance program may give Cabometyx free to people who qualify; no income limit is published.

Trial supply: the EASE page for doctors describes a free trial for new patients regardless of insurance type.

Phone: 1-844-900-3273, 8AM to 8PM ET, Monday to Friday.

Source: Cabometyx cost and financial support and EASE for Cabometyx

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Exelixis, Inc. via DailyMed · 2025-10-19. CABOMETYX- cabozantinib tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3850cce2-6137-42e5-a792-d318c4a4b3b5
  2. U.S. Food and Drug Administration · 2025-03-26. CABOMETYX approval history, NDA 208692. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692
  3. U.S. Food and Drug Administration · 2025-03-26. FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET. https://www.fda.gov/drugs/cancer-approvals/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet
  4. The New England Journal of Medicine via PubMed · 2025-02-13. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. https://pubmed.ncbi.nlm.nih.gov/39282913/
  5. ClinicalTrials.gov. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors. https://clinicaltrials.gov/study/NCT03375320
  6. Exelixis, Inc. via DailyMed · 2025-10-18. COMETRIQ- cabozantinib kit / COMETRIQ- cabozantinib capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34
  7. U.S. Food and Drug Administration · 2026-08-14. Cabozantinib S-malate tablets (MSN), ANDA 213878. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213878
  8. U.S. Food and Drug Administration · 2026-10-16. Cabozantinib S-malate tablets (Cipla), ANDA 217870. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217870
  9. Ipsen Biopharmaceuticals, Inc. via DailyMed · 2024-10-11. SOMATULINE DEPOT- lanreotide acetate injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d
  10. Advanced Accelerator Applications USA, Inc. via DailyMed · 2026-01-15. LUTATHERA- lutetium lu 177 dotatate injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55
  11. Novartis Pharmaceuticals Corporation via DailyMed · 2026-06-01. AFINITOR- everolimus tablet AFINITOR DISPERZ- everolimus tablet, for suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04
  12. Pfizer Laboratories Div Pfizer Inc via DailyMed · 2026-02-20. SUTENT- sunitinib malate capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c
  13. Merck Sharp & Dohme LLC via DailyMed · 2026-09-24. WELIREG- belzutifan tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13e15ee0-d679-4fa9-9430-e2e2170474da
  14. Exelixis. Cost & Financial Support | CABOMETYX® (cabozantinib). https://www.cabometyx.com/cost-financial-support
  15. Exelixis. Exelixis Access Services® (EASE) | CABOMETYX® (cabozantinib). https://www.ease.us/cabometyx/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Cabometyx by email

We'll email you when Cabometyx's FDA label changes, when the FDA acts on it, and when new trials for Neuroendocrine Tumors open. Unsubscribe anytime.

You'll get, for Neuroendocrine Tumors:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site